Found "Public health policy": 1,100 results
Sort by
Sort by
Relevance
Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand.(2011)
Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand
Pattara Leelahavarong1*, Yot Teerawattananon1, Pitsaphun Werayingyong1, Chutima Akaleephan2, Nakorn Premsri3, Chawetsan Namwat3, Wiwat Peerapatanapoki
Economic Evaluation of 3-Drug Antiretroviral Regimens for the Prevention of Mother-to-Child HIV Transmission in Thailand (2015)
Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,
A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines (2016)
Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1
Abstract
Background
For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Abstract
BACKGROUND:
Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis
Publication: Identifying priority technical and contextspecific issues in improving the conduct, reporting and use of health economic evaluation in low- and middle-income countries
The use of economic evaluation in healthcare policies and decision-making, which is limited in low- and middle-income countries (LMICs), might be promoted through the improvement of the conduct and reporting of studies. Although the literature indicates that there are many issues affecting the condu
A protocol for a systematic literature review of economic evaluation studies of interventions to address antimicrobial resistance
Abstract
Background
Antimicrobial resistance (AMR) is accelerated by the widespread and often indiscriminate use of antimicrobials in humans, animals, and the environment. In 2015, the World Health Organization recognised AMR as one of the top ten global health threats, due to its potential to n
Is it Worthwhile to Introduce Pneumococcal Conjugate Vaccine into the Routine Immunization Services?
In Bhutan, respiratory infections are some of the major causes of morbidity and mortality in children. Pneumonia, an infection of the lungs, is among the top 10 common
causes of children’s death in the country. Not only does it impose costs on society that may not be immediately visible (e.g. produ
High-Cost Users Still Came to Hospitals During the COVID-19 Pandemic in Thailand
Over the past 5 years, HCUs (i.e., top 5% of the population) utilized ~50% of the annual health expenditure, confirming that even during the pandemic year of 2020, the HCU phenomenon still existed.
The characteristics of HCU patients remained relatively the same from 2016 to 2020, in terms of pro
Value Distribution in New Branded Medicines: How Much Benefits Patients Versus Manufacturers?
Thailand has successfully implemented economic evaluation to inform the inclusion of new, branded medicines within its National List of Essential Medicines (NLEM). This method can be used to assess the health value that new medicines will generate for patients after accounting for the health los
10 / Page